Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes
About this item
Full title
Author / Creator
Marouf, Bushra Hassan, MSc, PhD , Iqbal, Zohaib, MBChB, MSc, MRCP , Mohamad, Jamal Basheer, MBChB, FRCP , Bashir, Bilal, MBBS, MRCP , Schofield, Jonathan, MBChB, FRCP, PhD , Syed, Akheel, MBBS, FRCP, PhD , Kilpatrick, Eric S., MD, FRCPath , Stefanutti, Claudia, MD, PhD and Soran, Handrean, MBChB, MSc, MD, FRCP
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
ABSTRACTPurposeProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are novel drugs that have proven efficacy in improving cardiovascular outcomes. Roles for the PCSK9 molecule in metabolic pathways beyond LDL receptor processing and cholesterol homeostasis are well established. PCSK9 genetic variants associated with lower LDL-C levels...
Alternative Titles
Full title
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2636143225
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2636143225
Other Identifiers
ISSN
0149-2918
E-ISSN
1879-114X
DOI
10.1016/j.clinthera.2021.12.005
